Molecular Cancer Therapeutics最新文献

{"title":"Abstract A012: Targeting proteasome vulnerabilities for the treatment of monosomy 7 associated blood disorders","authors":"Haijiao Zhang, Basil Allen, D. Bottomly, P. Ryabinin, Schannon K Mcweeney","doi":"10.1158/1538-8514.synthleth24-a012","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a012","url":null,"abstract":"\u0000 Monosomy 7 is among the most frequent cytogenetic abnormalities in hematological disorders and is associated with short survival and drug resistance. Despite its high prevalence and detrimental impact, the therapeutic vulnerabilities underlying monosomy 7-associated blood disorders remain largely elusive, impeding progress toward improved patient care. The homeostatic cellular requirement for a normal dosage of essential genes creates an opportunity to target vulnerabilities that arise due to reduced levels of proteins encoded by a haploinsufficient essential gene. Briefly, the loss of one copy of a dosage-sensitive essential gene (gene X), in combination with the inhibition of itself or a related gene (gene Y), or an associated pathway results in lethal consequences for cells. The remarkable and selective clinical efficacy of lenalidomide for the treatment of del(5q) MDS has demonstrated how allelic haploinsufficiency underlies the sensitivity to this drug by synthetic lethality. Differential expression analysis of gene and protein expression in primary AML samples with monosomy 7 revealed significant downregulation of multiple proteasome pathway members at the protein level, but not at the RNA level. Primary AML samples with -7/del(7q) exhibited increased sensitivity (low IC50) to the proteasome inhibitor bortezomib, as evidenced by two independent ex vivo drug screening cohorts (the Beat AML and the FIMM study). Chromosome 7 harbors four proteasome subunits, PSMA2, PSMC2, PSMG3, and SEM1. We performed gene expression, protein expression, copy number analysis, and individual gene knockout experiments. The results have revealed PSMA2 to be a haploinsufficient essential gene on chromosome 7. PSMA2 knockout confers leukemia a growth disadvantage for multiple AML cell clines in both TP53 wild-type and knockout backgrounds. We generated PSMA2 isogenic hemizygous deletion and diploid single-cell clones. PSMA2 hemizygous deletion cells exhibited approximately half the protein expression compared to diploid controls, confirming that PSMA2 is a haploinsufficient gene. PSMA2hemizygous deletion single-cell clones showed significantly enhanced sensitivity to all three evaluated proteasome inhibitors (bortezomib, ixazomib, and carfilzomib), aligning with the sensitivity observed in primary -7/del(7q) leukemia samples. PSMA2 hemizygous deletion cell clones displayed increased p38 and decreased pERK levels upon treatment with proteasome inhibitors, potentially contributing to their increased sensitivity to proteasome inhibitors. Proteomics analysis and in vivo validation is ongoing. As such, we have identified haploinsufficient essential gene PSMA2 mediated proteasome pathway vulnerability in monosomy 7 associated leukemia and further showed that proteasome inhibitors as promising therapeutic approaches for treating hematological disorders associated with monosomy 7.\u0000 Citation Format: Haijiao Zhang, Basil Allen, Daniel Bottomly, Peter Ryabinin, Schannon K. ","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141360653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract IA005: Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies","authors":"Zuzana Tothova","doi":"10.1158/1538-8514.synthleth24-ia005","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-ia005","url":null,"abstract":"\u0000 Splicing modulation is a promising treatment strategy pursued to date only in splicing-factor mutant cancers; however, its therapeutic potential is poorly understood outside of this context. Like splicing factors, genes encoding components of the cohesin complex are frequently mutated in myeloid malignancies, including 15-20% of myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML), where they are associated with poor outcomes. I will discuss our recent findings identifying cohesin mutations as biomarkers of sensitivity to drugs targeting splicing-factor SF3B1 (H3B-8800 and E-7107) and describe the mechanism by which drug-induced alterations in splicing of DNA repair genes, such as BRCA1 and BRCA2, underlie this sensitivity. We have demonstrated that treatment of cohesin-mutant cells with SF3B1 modulators results in impaired DNA damage response, accumulation of DNA damage, and increased sensitivity to PARP inhibitors and a panel of chemotherapeutic agents in vitro and in vivo, using AML cell lines and patient-derived xenograft models. Furthermore, we identified RAD51 foci formation as a predictive biomarker of sensitivity to SF3B1 splicing modulation alone or followed by sequential treatment with PARP inhibition and chemotherapy, and have identified additional non-cohesin mutant subtypes of MDS/AML and ovarian and breast cancer which are sensitive to this therapeutic approach. Our findings expand the potential therapeutic benefits of SF3B1 splicing modulators to include cohesin-mutant MDS/AML and we propose this as broader strategy for therapeutic targeting of other DNA damage-repair deficient cancers.\u0000 Citation Format: Zuzana Tothova. Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA005.","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141360983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A023: Determining genetic interaction from double knockout CRISPR screening","authors":"J. P. Shen, Yue Gu, S. Chowdhury","doi":"10.1158/1538-8514.synthleth24-a023","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a023","url":null,"abstract":"\u0000 Background For decades double knockout (KO) perturbation screens were limited to model organisms such as S. pombe and S. cerevisiae. CRISPR technology has revolutionized genetic interaction discovery by allowing large scale screening in human cell lines, organoids, and mouse models. However, there remains much uncertainty regarding the optimal way to determine the presence of genetic interaction from the raw data generated from these large scale double perturbation experiments. Here we compare two different analysis methods run on the same normalized dataset to determine to what degree does the analysis method influence the determination of genetic interaction. Methods A publicly available genetic interaction dataset containing 24,908 double knock-out constructs across three cell lines (Hela, A549, 293T) in four time points (day 3, 14, 21, 28) and two replicates generated from a pair-wise CRISPR-Cas9 KO screen was used for analysis (Shen et al, Nature Methods, 2017). These data were used to measure single gene fitness scores for 73 known cancer driver genes and all 2628 pair-wise interactions using (1) the numerical Bayesian method from Shen et al, called CTG (Compositional and Time-course-aware Genetic analysis), and (2) the variational Bayesian method GEMINI (Zamanighomi et al, Genome Biology, 2019). Results Single gene KO fitness measurements from CTG and GEMINI were highly correlated for all three cell lines (pearson r 0.678, 0.604, 0.784 for HeLa, A549, and 293T, respectively; p< 0.1 x10-8 for each). In contrast, correlation of genetic interaction scores between the two methods was essentially random: HeLa r= -0.0143, p= 0.47, A549; A549 r= -0.0476, p=0.015; 293T r= -0.0135, p= 0.49. Of 52 synthetic lethal interactions identified by CTG in HeLa at z-score cut off -3, none were identified by GEMINI at same Z cutoff. Conversely of 4 interactions identified by GEMINI, none were identified by CTG. Similarly in A549, of 57 interactions identified by CTG none were identified by GEMINI, of 3 interactions identified by GEMINI none were identified by CTG. Restricting to genetic interactions that were validated in low-throughput drug-drug assays, of 5 synthetic lethal interactions found in HeLa by CTG (CHEK1-MAP2K1, CHEK1-TYMS, ADA-CHEK1, ATM-CHEK1, CDK9-CHEK1) all but CHEK1-TYMS were validated in low-throughput assays. However none of the 5 were scored as hits by GEMINI. Of 3 interactions scored as synthetic lethal in A549 (PRKDC-RRM2, CDK9-PRKDC, CDK4-PRKDC) all but PRKDC-RRM2 were validated, none of the 3 were scored as hits by GEMINI. Conclusions This study highlights dramatic differences in calculated genetic interaction scores from two different computational algorithms applied to the same experimental data. With only 8 of 2628 (0.3%) interactions tested in validation experiments it is not currently possible to know the ground truth in order to assess which method is most accurate. The generation of synthetic genetic interaction data will be a","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141362925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine","authors":"Eleonora Messuti, B. Duso, Alessia Castiglioni, G. Tini, Emanuele Bonetti, Giuseppe Ciossani, Silvia Monzani, Daria Khuntsariya, Marcus Braun, Zdeněk Lánský, Luigi Scietti, Luca Mazzarella","doi":"10.1158/1538-8514.synthleth24-a013","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a013","url":null,"abstract":"\u0000 There is great interest in the identification of biomarkers to guide development of antibody-drug conjugates (ADC). Most research has focused on target expression, but key predictors of payload efficacy have not been indeitifed. NF1 is a tumor suppressor classically considered as an inhibitor of RAS signaling, and often mutated in metastatic HER2+ breast cancer (BC). We screened multiple approved drugs for differential sensitivityin CRISPR-engineeredf NF1 KO cells. HER2-targeted agents (small molecules or antibodies) were found to be less effective upon NF1 loss; surprisingly, we identified increased sensitivity to the approved ADC T-DM1, but not to Trastuzumab Deruxtecan (T-Dxd). We then elucidated the underlying molecular cause employing in vivo, in vitro and in vitro reductionist systems. To measure in vivo MT dynamics, we transiently transfected the MT end-binding protein EB3- GFP and reconstructed MT trajectories by live-cell imaging. Upon DM1 treatment, KO cells showed a highly significant reduction in MT speed, demonstrating a direct role for NF1 on MT dynamics in cells. In tubulin polymerization assays, recombinant NF1 greatly accelerated polymerization and completely rescued DM1-induced inhibition. NF1 induced significant MT bundling, a defining feature of many MT-associated proteins, which generates signal indistinguishable from true MT polymerization in turbidity assays. To follow the dynamics of individual microtubules, we applied Total Internal Reflection (TIRF) microscopy on glass-immobilized MTs. As expected, polymerization in the presence of NF1 led to a dose-dependent significant increase in MT dynamics (fraction of elongating MTs, elongation speed, catastrophe rate). Expectedly, DM1 led to significant reduction in the fraction of elongating MTs and speed, but these defects were completely or partially rescued by NF1. Importantly, DM1 did not only lead to MT shortening (as proposed by the current model), but also to clear and frequent MT fracturing, indicating that the drug is not only engaging MT ends but also intra-tubular binding sites. This is consistent with recent models of MT formation which incorporate the frequent presence of areas of discontinuity or damage induced by mechanical stress, exposing intratubular DM1 binding sites. Interestingly, adding NF1 to DM1-treated MTs generated areas of de novo intra-tubular tubulin insertion, coincident with damaged sites, suggesting an entirely novel role for NF1 in MT repair. In conclusion, we provide evidence for a model in which maytansinoids bind not only to soluble tubulin dimers and MT ends, but also to intratubular damaged sites. Thus, the number of binding sites in cells would be proportional to MT damage, suggesting a mechanism for differential efficacy across tumor types and a potential avenue for combinatorial drug development. These results prompt the use of NF1 as a biomarker to select patients for ADC treatment. Funding: FIEO fellowship 2023, AIRC (n25791), Italian ","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141363110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis","authors":"E. Lai, Manuela Neri, E. Sanna, Sonia Nemolato, F. Bardanzellu, M. Scartozzi, Sabrina Giglio, A. Macciò, C. Madeddu","doi":"10.1158/1538-8514.synthleth24-a020","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a020","url":null,"abstract":"\u0000 Background and aim of the study: Currently, platinum sensitivity (PS) is a prerequisite for first-line PARP inhibitors (PARPi) in locally advanced and relapsed high grade serous ovarian cancer (HGS-OC). BRCA mutations are recognized as predictive of PS and, therefore, of response to PARPi . Notably, platinum and PARPi cytotoxic action is mainly related by their ability of inducing p53-mediated apoptosis. Therefore, the integrity of p53 machinery is crucial for platinum-related activity whereas the presence of p53 mutation is a fairly frequent event in ovarian cancer, particularly in HGS-OC and in BRCA mutated ones. Patients and methods: We prospectively analyzed 208 women with primary ovarian cancer undergoing surgery at the Department of Gynecologic Oncology, ARNAS G. Brotzu, Cagliari, Italy, between 2019 and 2023. Somatic NGS analysis was performed to detect BRCA and HRD mutations. TP53 mutations were classified according to according to hotspot, structural (missense or nonsense) and functional classification as “gain of function” (GOF) or “loss of function” (LOF), based on the IARC TP53 database. Comparative testing with Fisher's exact test was used to examine TP53 mutation distribution and associations with clinicopathologic factors and PS. The BRCA mutation status was further used to stratify the analysis. Results: Globally, we included 127 adult HGS-OC pts. 84.2% had stage III-IV disease. TP53 mutation was found in 83.4 % of the entire cohort. Somatic BRCA mutations were found in 28.3% pts. Overall, HGS-OC with somatic BRCA mutations had higher TP53 mutation frequency (88.8%) when compared to BRCA WT (81.3%, p=0.1510). Employing the structural classification scheme, most cancers harbored a missense TP53 mutation (76.5%). LOF TP53 mutations were found in 59.4% while GOF in 31.2%. No significant disparity was observed in the distribution of specific TP53 mutations within each classification scheme between cases with BRCA mutations and those without. As for BRCA mutated pts, TP53 WT were all PS. Among those p53 mutated, GOF mutations were associated with PS in 7 pts and platinum resistance in 3 pts; LOF mutations were associated with PS in 7 pts and platinum resistance in 12 pts. The difference in distribution of PS between functional categories of p53 mutations was significant (p=0.0291). As for BRCA WT pts, TP53 WT were all PS. Among TP53 mutated, GOF mutations were associated with PS in 14 pts and platinum resistance in 10 pts; viceversa, LOF mutations were associated with PS in 19 pts and platinum resistance in 25 pts, even if these findings were not statistically significant (p=0.2357). Of relevance, in 5 cases where LOF mutations of p53 was associated with null expression of HIC p53, patients were refractory to platinum-based chemotherapy. Conclusions: Even if preliminary, our data show that HGS-OC harboring p53 null mutations are the poorest prognostic subgroup, especially in terms of PS. Further studies are needed to confirm our find","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141365227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B013: Deep learning-based prediction of synthetic essentialities in CTNNB1-mutated hepatocellular carcinoma","authors":"Tyler M. Yasaka, Michael J. Kasper, Li-Ju Wang, Michael Ning, Yufei Huang, S. Monga, Yu-Chiao Chiu","doi":"10.1158/1538-8514.synthleth24-b013","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-b013","url":null,"abstract":"\u0000 Background: Synthetic essentiality represents a promising therapeutic approach by identifying genes that are necessary for the proliferation and survival of tumors harboring hard-to-target gene alterations. Understanding and accurately predicting synthetic essential genes, through genetic dependencies, may reveal therapeutically effective drug targets in a specific molecular context. Deep learning, as exemplified by our published DeepDEP model, has the potential to capture intricate multi-omic profiles for such prediction tasks. However, the validity of such tools in specific biological contexts remains to be fully examined and presents a major obstacle to adoption by researchers. Materials and Methods: To address this gap, we conducted a case study in which we screened for synthetic essential genes for one of the most frequently mutated and yet undruggable genes, CTNNB1, in hepatocellular carcinoma (HCC). Specifically, we predicted the genetic dependencies of each HCC patient in The Cancer Genome Atlas (TCGA; n=346) by DeepDEP and identified potential dependencies that were intensified with the presence of CTNNB1 mutations. The top 10 genes, ranked by p-value of differential gene-effect scores for CTNNB1-mutated (n=92) versus CTNNB1-WT HCC (n=254), were reviewed in the literature to validate their essentiality in CTNNB1-mutated HCC as well as their potential for pharmacologic inhibition. Survival analysis was performed using published data from the IMBrave150 trial to validate one of the findings. Results: Experimental evidence in the literature supported the essentiality of many of the top 10 predicted genes for CTNNB1-mutated HCC, including one gene with mechanistic evidence of being a transcriptional co-activator of β-catenin target genes. Furthermore, several of these genes have known pharmacologic inhibitors which are either natural compounds or FDA-approved drugs. One example was PDGFB, which encodes a ligand activating the PDGF signaling pathway. PDGF signaling is targeted by sorafenib, an FDA-approved first line drug for HCC. Survival analysis of the sorafenib-treated arm of the IMBrave150 trial showed that patients with mutated CTNNB1 had improved progression-free survival compared to those with wild-type CTNNB1 (p = 0.044). Conclusions: Our study illustrates a potential application of deep learning to identify synthetic essential genes, including genes with readily available pharmacologic inhibitors, for targeting challenging gene alterations. Remarkably, our tool demonstrates the ability to predict cancer dependencies with molecular subtype specificity, suggesting a potential for in silico screening of gene dependencies to facilitate drug discovery and personalized medicine approaches. Our current efforts are focused on optimizing this computational pipeline and making it publicly available for cancer researchers.\u0000 Citation Format: Tyler M. Yasaka, Michael Kasper, Li-Ju Wang, Michael Ning, Yufei Huang, Satdarshan P Monga, Yu-Chiao C","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141365448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers","authors":"Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter C. DeWeirdt, John G Doench, William C Hahn","doi":"10.1158/1538-8514.synthleth24-b015","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-b015","url":null,"abstract":"\u0000 This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR014) of the Conference Program/Proceedings.\u0000 Citation Format: Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter DeWeirdt, John Doench, William C Hahn. Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B015.","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141363909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A011: Enhancing chaperone-mediated autophagy to impede glioblastoma growth","authors":"Wanjun Tang, Karrie Mei Yee Kiang, Gilberto Ka Kit Leung","doi":"10.1158/1538-8514.synthleth24-a011","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a011","url":null,"abstract":"\u0000 Chaperone-mediated autophagy (CMA) is a selective form of autophagy that targets proteins with the KFERQ-like motif for lysosomal degradation. This process involves the binding of substrate proteins to the chaperone HSC70 and their subsequent transport to the receptor LAMP2A on the lysosome membrane for degradation. Previous studies have shown a significant increase in the expression level of LAMP2A and the CMA activity in glioblastoma (GBM). However, the comprehensive role of CMA in GBM pathogenesis remains unclear. In this study, we observed a progressive elevation in LAMP2A expression with increasing GBM cell confluence. Notably, inhibition of CMA through LAMP2A knockdown markedly promoted GBM growth in orthotopic mouse models, accompanied by upregulation of positive cell cycle regulators. Conversely, overexpression of LAMP2A delayed GBM cell growth and increased sub-G1 cell percentages. Treatment with CMA activators induced cell death in GBM cells while preserving normal astrocyte viability at equivalent concentrations. Our results suggest that the upregulated expression of LAMP2A in GBM cells may be influenced by the tumor microenvironment rather than being a primary driver of GBM aggressiveness. Furthermore, activating CMA could serve as a potential therapeutic strategy to inhibit GBM growth while safeguarding normal cell viability.\u0000 Citation Format: Wanjun Tang, Karrie Mei Yee Kiang, Gilberto Ka Kit Leung. Enhancing chaperone-mediated autophagy to impede glioblastoma growth [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr A011.","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141365687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract IA018: Vulnerabilities of TP53-mutated AML and therapeutic implications","authors":"Shruti Bhatt","doi":"10.1158/1538-8514.synthleth24-ia018","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-ia018","url":null,"abstract":"\u0000 Acute myeloid leukemia (AML) is a complex and genetically diverse with an overall survival rate of less than 32%. Despite the remarkable success of targeted therapy in mediating remission, the emergence of acquired resistance remains a major clinical challenge to overcome. The prevailing understanding of acquired resistance identifies successive genetic changes as the primary cause.TP53 mutations are found in 70-80% of acute myeloid leukemia (AML) patients with complex karyotypes and associated with resistance towards both conventional chemotherapy and newly approved venetoclax plus azacytidine (VEN/AZA) combination. By using CRISPR-Cas9-edited isogenic AML cells harboring, mutation (6 missense mutations) or deletion (KO) of TP53, we found that TP53 mutant/KO cells are less sensitive to etoposide or VEN-AZA induced apoptosis compared to WT without defect in G1 arrest. Surprisingly, we found that TP53-mutant and TP53-wild-type (WT) isogenic AML cells and primary tumors (n=40) had comparable mitochondrial outer membrane permeabilization (MOMP) at baseline, despite the key role of TP53 in transcriptionally activating proapoptotic regulators of MOMP (such as BAX, PUMA, and NOXA). Based on these findings, we hypothesize that the targets downstream of mitochondrial permeabilization drive resistance to HMA/VEN combinations in TP53 mutant disease. By leveraging unbiased bulk RNA-seq and proteomics, and whole genome CRISPR-cas9 screen we identified IAPs as functional vulnerability. Collectively we reveal novel chemoresistance mechanisms in TP53 mutant/KO downstream of MOMP and provide a targeting strategy to improve existing therapy by targeting non-transcriptional function of TP53 in overcoming therapy resistance.\u0000 Citation Format: Shruti Bhatt. Vulnerabilities of TP53-mutated AML and therapeutic implications [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA018.","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141361213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract A026: Single-cell landscape deciphering cancer Single-cell landscape deciphering cancer cell-of-origin and cellular heterogeneity in malignant transformation of 13 major tissues","authors":"Ruihan Luo","doi":"10.1158/1538-8514.synthleth24-a026","DOIUrl":"https://doi.org/10.1158/1538-8514.synthleth24-a026","url":null,"abstract":"\u0000 Deciphering disease progression and the sophisticated tumor ecosystems is imperative for exploring tumorigenesis mechanisms and developing novel prevention strategies. Here, we dissected heterogeneous tissue microenvironments during malignant transitions by leveraging data from 4,972,145 single cells in 1396 samples from 62 datasets spanning 13 major tissue types. Within transitional stem-like subpopulations highly enriched in precancerous lesions and cancers, we identified 30 recurring cellular states, including hypoxia and epithelial senescence, revealing a high degree of plasticity in epithelial stem cells. By characterizing the dynamics of stem-cell crosstalk with the microenvironment along the pseudotime axis, we uncovered distinct roles of ANXA1 at different stages of tumor development. ANXA1 expression levels in stem cells were decreased from the healthy to the precancerous stages, which promoted inflammatory responses by recruiting neutrophils and regulating monocyte differentiation towards M1 macrophages. In contrast, during malignant progression, upregulated ANXA1 fostered M2 macrophage polarization and cancer-associated fibroblast transformation. Our spatiotemporal analysis further provided insights into mechanisms responsible for immunosuppression. Collectively, this study provided a systematic view of cancer origins, and suggested that restoring and maintaining the balance of inflammation and their mediators (e.g., AnxA1/FPRs signaling) may represent a novel approach to control the evolution of precancerous lesions and mitigate the risk for cancer development.\u0000 Citation Format: Ruihan Luo. Single-cell landscape deciphering cancer cell-of-origin and cellular heterogeneity in malignant transformation of 13 major tissues [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr A026.","PeriodicalId":18791,"journal":{"name":"Molecular Cancer Therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141361882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}